Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055185 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients
A Phase 2 study, sponsored by Progenics Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00055185 is a Phase 2 study that has completed, run by Progenics Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT00055185, a Phase 2 study, has completed, sponsored by Progenics Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.
Interventions
- DRUG CD4-IgG2 (PRO 542)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055185
The ClinicalTrials.gov registry entry for NCT00055185 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Progenics Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD4-IgG2 (PRO 542) is the first listed.
NCT00055185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055185 about?
NCT00055185 is a clinical study titled "Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients". The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.
What is the current status of trial NCT00055185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2003-04. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00055185?
The interventions under investigation include: CD4-IgG2 (PRO 542) (DRUG).
Who is sponsoring clinical trial NCT00055185?
This trial is sponsored by Progenics Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.